Free Publications

Search for cll returned 217 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

LLS Applauds Data From Phase 2 Study of Venetoclax for High-Risk CLL Patients

LLS has supported this research for 13 years through its Specialized Center of Research Program

White Plains, N.Y. (August 19, 2015) – The Leukemia & Lymphoma Society (LLS) welcomes the news that an investigational therapy to treat patients with a high-risk subset of chronic lymphocytic leukemia (CLL) has shown very positive results in a Phase II clinical trial. There are more than 126,000 patients in the United States currently living with CLL, a typically slow-moving blo ...

  • Photo
Read more

LLS Applauds Approval of New Therapy for CLL Patients

Development of the drug, venetoclax, was supported by LLS funding

Rye Brook, NY – April 12, 2016 – The approval of a new therapy for patients with a high-risk form of chronic lymphocytic leukemia (CLL) is welcome news for patients for whom there have been few other options, The Leukemia & Lymphoma Society (LLS) said today. The U.S. Food and Drug Administration has approved venetoclax (Venclexta ®) to treat patients with a rare subset of CLL in which a piece of chromosome ...

  • Photo
Read more

Real-world Patient Experiences & Evidence-based Treatment Strategies in CLL/SLL and FL

In collaboration with PRIME®
  1.0 AMA PRA Category 1 Credit™/1.0 ACPE credit for pharmacists/1.0 AAPA Category I CME credit for physician assistants/ 1.0 AANP credit for nurse practitioners/1.0 CE contact hour for nurses, case managers and certified health education specialists
 

Read more

Managing Toxicities of Novel Therapies and Coordinating Care for CLL/SLL and FL Patients

In collaboration with PRIME®
  1.0 AMA PRA Category 1 Credit™/1.0 ACPE credit for pharmacists/1.0 AAPA Category I CME credit for physician assistants/ 1.0 AANP credit for nurse practitioners/1.0 CE contact hour for nurses, case managers and certified health education specialists
 

Read more

Investigational CLL Therapy to Get Priority Review by FDA

Marking another promising advance for the treatment of patients with chronic lymphocytic leukemia, including those with a rare subset of this blood cancer, the U.S. Food and Drug Administration (FDA) has granted priority review for an investigational compound that has shown positive results in a Phase II clinical trial. Venetoclax has shown great potential as a new way of treating CLL patients who have received at least one prior therapy. It also appears to be effective for patients with ...

Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.